Rosa Schleife am Rathaus Münster
C. Verloh, N. Oxenius
MTA Dialog 12/2020
The TOSYMA RCT: Increasing the study sample size to assess the effect of DBT on interval cancer rates in mammography screening
W. Heindel, S. Weigel, L. Kerschke, K. Spieker, H.W. Hense, J. Gerss
BMJ Open. 2020 Nov 2022
Incidence of advanced-stage breast cancer in regular participants of a mammography screening program: a prospective register-based study
L. Khil, J. Heidrich, I. Wellmann, V. Kääb-Sanyal, S. Weigel, W. Heindel, H.W. Hense, O. Heidinger
BMC Cancer. 2020 Mar 4;20(1):174. doi: 10.1186/s12885-020-6646-5
Stratification of Breast Cancer Risk in Terms of the Influence of Age and Mammographic density
S. Weigel, W. Heindel, C. Dietz, U. Meyer-Johann, A. Graewingholt, W.H. Hense
Rofo. 2020 Feb 27. doi: 10.1055/a-1100-0016
High-risk breast cancer surveillance with MRI: 10-year experience from the German consortium for hereditary breast and ovarian cancer
U. Bick, C. Engel, B. Krug, W. Heindel, E. M. Fallenberg, K. Rhiem, D. Maintz, M. Golatta, D. Speiser, D. Rjosk-Dendorfer, I. Lämmer-Skarke, F. Dietzel, K. Werner, F. Schäfer, E. Leinert, S. Weigel, S. Sauer, S. Pertschy, T. Hofmockel, A. Hagert-Winkler, K. Kast, A. Quante, A. Meindl, M. Kiechle, M. Loeffler, R. K. Schmutzler, the German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC)
Breast Cancer Res Treat (2019). doi: 10.1007/s10549-019-05152-9
Strukturierte und qualitätsgesicherte Früherkennung: Eine wichtige Säule im Kampf gegen Brustkrebs
W. Heindel, C. Verloh, S. Weigel
Onkologische Pharmazie; 21. Jahrgang; Nr. 1/2019; ISSN-Nr. 1437-8825